Clinical Trial: A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07444307) titled 'A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus' on Feb. 12.

Brief Summary: This study is a single-arm, open-label clinical study designed to evaluate the safety and tolerability of QT-019B in subjects with refractory SLE and to determine the RD. The study has two phases: dose escalation and dose expansion, with a planned enrollment of 18-24 subjects.

Study Start Date: Dec. 15, 2025

Study Type: INTERVENTIONAL

Condition: Systemic Lupus Erythematosus (SLE)

Intervention: DRUG: QT-019B Cell Injection

The study will begin by enrolling the first subject in Dose A (1x106/kg),...